Development of treatment
for patients

MP2021

MP2021

TM4SF19 – Novel Target for Bone Health & inflammatory diseases
First-in-class bone diseases therapy

TM4SF19

  • A novel target with dual effects on bone loss and inflammation
  • Only expression when immune balance is chronically disrupted
  • A substance that directly acts on M1 macrophages linked to inflammatory cytokines and osteoclasts responsible for bone resorption

MP2021 : Competitive Inhibitor for TM4SF19

  • MP2021 targets TM4SF19, a novel protein involved in osteoclast formation
  • MP2021 is a Fc-fusion protein that competitively inhibits TM4SF19.
  • Osteoclast differentiation is inhibited in both KO and LELΔ osteoclasts, resulting in increased bone mass, and that the LEL region of TM4SF19 is required for its function.
  • Efficacy
  • Significantly inhibits bone-loss and restores bone balance (Rheumatoid Arthritis, Osteoporosis)

    Inhibition of bone metastasis (anticancer)

    Inhibition of muscle loss

    Reduction of visceral white fat (fatty liver prevention)

  • Potential to expand to broader bone diseases and healthy aging

Efficacy study for IND completed

Significantly inhibits bone-loss and restores bone balance in osteoporotic model.

Confirmed improvement in BMD, BV/TV, Tb.N, and Tb.Sp.

Suppresses adipocyte differentiation and inflammation, prevent obesity and bone loss, and promote browning of white adipose tissue to enhance thermogenesis.


TOX study for IND completed

Highest dose selected as the NOAEL

Safe due to distinctive MoA of TM4SF19.

Presentations & Publications

Total 0

  • Mar, 2025

    Tm4sf19 inhibition ameliorates inflammation and bone destruction in collagen-induced arthritis by suppressing TLR4-mediated inflammatory signaling and abnormal osteoclast activation

    Bone Research
  • Nov, 2024

    MIMERET, a Novel Mitochondrial-Targeted Drug, Improves Hepatic Steatosis by Stimulating Mitochondrial Fatty Acid Beta-Oxidation to Prevent Lipid Accumulation

    AASLD 2024
  • Nov, 2024

    Vactosertib, a TGF-β signaling inhibitor, in combination with Durvalumab increased mOS in ≥2L treatment of patients with PD-L1-positive advanced NSCLC

    SITC 2024
  • Aug, 2024

    The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial

    Nature Communications
  • Jul, 2024

    Oral transforming growth factor-beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti-tumor immunity

    Cancer Communications
  • Nov, 2023

    Tm4sf19 deficiency inhibits osteoclast multinucleation and prevents bone loss

    Metabolism 151
  • Apr, 2023

    Vactosertib combined treatment with T1-44, a PRMT5 activity inhibitor, improves the survival and inhibits tumor invasion of murine pancreatic cancer model

    American Association for Cancer Research 2023(AACR 2023)
  • Feb, 2023

    Combination treatment of T1-44, a PRMT5 inhibitor with Vactosertib, an inhibitor of TGF-β signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors

    Cell Death and Disease (2023)
  • Jan, 2023

    Discovery of TRD-93 as a novel DRAK2 inhibitor

    BULLETIN OF THE KOREAN CHEMICAL SOCIETY
  • Dec, 2022

    MAST4 controls cell cycle in spermatogonial stem cells

    Cell proliferation(IF : 8.755)
  • Dec, 2022

    Therapeutic Implications of TGF-β Pathway in Desmoid Tumor Based on Comprehensive Molecular Profiling and Clinicopathological Properties

    Cancers
  • Oct, 2022

    ESRP1-regulated isoform switching of LRRFIP2 determines metastasis of gastric cancer

    Nature communication
  • Sep, 2022

    Phase 1b Study of Vactosertib in Combination with FOLFOX in Patients with Metastatic Pancreatic Ductal Adenocarcinoma who have Failed First-Line Gemcitabine/nab-Paclitaxel

    AACR Special Conference on Pancreatic Cancer 2022
  • Jan, 2022

    Phase 1b Study of Vactosertib in Combination with nal-IRI plus 5FU/LV in Patients with Metastatic Pancreatic Ductal Adenocarcinoma who Failed First-Line Gemcitabine/nab-Paclitaxel

    ASCO GI 2022
  • Nov, 2021

    Tumor Microenvironment based on PD-L1 and CD8 T-cell infiltration correlated with the survival of MSS mCRC patients treated vactosertib in combination with pembrolizumab

    SITC 2021
  • Nov, 2021

    Spatial analysis of tumor-infiltrating lymphocytes correlates with the response of metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab

    SITC 2021
  • Jun, 2021

    Efficacy and Safety of Vactosertib and Pembrolizumab Combination in Patients with Previously Treated Microsatellite Stable Metastatic Colorectal Cancer

    ASCO 2021
  • Jun, 2021

    Phase 1b trial of Vactosertib in Combination with Pomalidomide in Relapsed Multiple Myeloma: A Corticosteroid-Free Approach by Targeting TGF-β Signaling Pathway

    ASCO 2021
  • Apr, 2021

    BAG2 Promotes Tumorigenesis and Metastasis by Regulating the Cathepsin B Cleavage in Triple Negative Breast Cancer Cells

    AACR 2021
  • Apr, 2021

    DRAK1 suppresses inflammation induced cervical cancer progression by targeting TRAF6 protein

    AACR 2021
  • Apr, 2021

    Beneficial effect of vactosertib combined with nal IRI5 FULV in pancreatic cancer treatment

    AACR 2021
  • Apr, 2021

    Genomic and transcriptomic analyses of desmoid tumor reveals enrichment of transforming growth factor beta responsive signature

    AACR 2021
  • Nov, 2020

    Vactosertib and Durvalumab as Second or Later Line Treatment for PD-L1 Positive Non-small Cell Lung Cancer: Interim Result

    SITC 2020
  • Sep, 2020

    Safety and Efficacy of Vactosertib, a TGFBR1 Kinase Inhibitor, in Combination with Paclitaxel in Patients with Metastatic Gastric Adenocarcinoma

    ESMO Congress 2020
  • May, 2020

    A Phase 1 study of TGF-β inhibitor, Vactosertib, in combination with Imatinib in patients with advanced desmoid tumor (aggressive fibromatosis)

    ASCO 2020
  • Nov, 2019

    Safety and Preliminary clinical activity of Vactosertib, a selective TGF-β receptor I kinase inhibitor, in combination with Durvalumab in advanced Non-small cell lung cancer patients with low PD-L1 expression

    SITC 2019
  • Nov, 2019

    Safety and preliminary clinical activity of Vactosertib, a selective TGF-β receptor I kinase inhibitor, in combination with Pembrolizumab in patients with metastatic colorectal or gastric cancer

    SITC 2019
  • Nov, 2019

    TGF-β as a promising therapeutic target for treating Osteosarcoma

    Innovation in AYA cancer
  • Jun, 2018

    TGF-β Responsive signature is associated with anti-tumor effect of Vactosertib, a potent oral TGF-β receptor type1(TGFBRI) inhibitor in patients with advanced solid tumors

    ASCO 2018